BLT.AX says CEO and Managing Director Dr Peter French Resigned, page-66

Hoyland , sure I understand those factors , the company was wrong footed by Gilead etc , so HCV is clearly not the ideal disease target , agreed . BUT, its what we have, [nearly] a first success to show the world . Without it , or after [possibly] it fails , the company will have no credibility left [it obviously has precious little now] . Remember , TT-034 has been touted as a potentially great one shot cure , for a couple of years now , like it or not , they must see it through . Who cares about transduction blah blah if it doesn't cure something .

Plus , changing focus at this point , would clearly point to a panic within the company .

Anyway , it matters not what is posted here , but its credibility that I am concerned with in the earlier post .

Enough from me .